Every quarter, ARM publishes fresh data that highlights sector trends in clinical trials, investment, and developer growth. We supplement our data releases with periodic commentary, the Sector Snapshot, that contextualizes what’s new, what’s important, and why it matters.
Note to our readers: As of Q1 2023, we have updated our approach to collecting sector data by building our data collection around identifying relevant drug assets within ARM’s technology scope. This approach has enhanced our data in multiple ways, including identifying 1,000+ undetected developers in our previous approach centered on identifying relevant clinical trials.
Our Q2 2023 sector data is now available below. Our next Sector Snapshot will be published alongside our Q3 2023 data.
Access a full breakdown of global clinical trials within the cell and gene therapy sector.
A quick glimpse at the total number of therapeutic developers globally.
An overview of investment figures, equity performance, and financial deals that shape the sector.
ARM commentary that spotlights notable trends and stories driving the sector. Our next Sector Snapshot will be published alongside our Q3 2023 data.
This edition highlights our new and improved cell and gene therapy sector data, a clinical pipeline outlook, and solutions to the sector’s workforce gap.
